109
edits
m (myeloma) |
|||
(4 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
'''CD56''' is a commonly available [[immunostain]] that is seen in a number of tumours. It is a sensitive marker of | '''CD56''' is a commonly available [[immunostain]] that is seen in a number of tumours. It is a sensitive [[neuroendocrine marker|marker of neuroendocrine differentiation]]. | ||
==Positive== | ==Positive== | ||
Line 12: | Line 12: | ||
*[[Extranodal NK/T-cell lymphoma, nasal type]]. | *[[Extranodal NK/T-cell lymphoma, nasal type]]. | ||
*[[Hepatosplenic T-cell lymphoma]]. | *[[Hepatosplenic T-cell lymphoma]]. | ||
*[[Plasma cell myeloma]] | |||
===Others=== | ===Others=== | ||
Line 17: | Line 18: | ||
*[[Solid pseudopapillary tumour]]. | *[[Solid pseudopapillary tumour]]. | ||
*[[Follicular dendritic cell sarcoma]]. | *[[Follicular dendritic cell sarcoma]]. | ||
==Occasionally positive== | |||
*[[Renal cell carcinoma]] ~18% of cases.<ref name=pmid20462442>{{cite journal |authors=Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P |title=Evaluation of neuroendocrine markers in renal cell carcinoma |journal=Diagn Pathol |volume=5 |issue= |pages=28 |date=May 2010 |pmid=20462442 |pmc=2876076 |doi=10.1186/1746-1596-5-28 |url=}}</ref> | |||
==See also== | ==See also== |
edits